Avoiding vicious circles: Mineralocorticoid receptor antagonism prevents vascular oxidative stress early after myocardial infarction

Hypertension

Volumn 50, Issue 5, 2007, Pages 842-843

  Brandes, Ralf P ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPLERENONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; DRUG DERIVATIVE; SPIRONOLACTONE;

CARDIOVASCULAR RISK; CIGARETTE SMOKING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; ENZYME ACTIVATION; GENE EXPRESSION; HEART INFARCTION; HORMONE ACTION; HUMAN; HYPERTENSION; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; MOUSE; RAT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II; ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MYOCARDIAL INFARCTION; OXIDATIVE STRESS; RATS; RECEPTORS, MINERALOCORTICOID; SIGNAL TRANSDUCTION; SPIRONOLACTONE;

EID: 35848942351     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.098699     Document Type: Note

References (12)

1. Nagata D, Takahashi M, Sawai K, Tagami T, Usui T, Shimatsu A, Hirata Y, Naruse M. Molecular mechanism of the inhibitory effect of aldosterone on endothelial NO synthase activity. Hypertension. 2006;48:165-171.
2. Mazak I, Fiebeler A, Muller DN, Park JK, Shagdarsuren E, Lindschau C, Dechend R, Viedt C, Pilz B, Haller H, Luft FC. Aldosterone potentiates angiotensin II-induced signaling in vascular smooth muscle cells. Circulation. 2004;109:2792-2800.
3. Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. 2006;20:1546-1548.
4. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
5. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res. 2005;97:946-953.
6. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504 -510.
7. Sartorio CL, Fraccarollo D, Galuppo P, Leutke M, Ertl G, Stefanon I, Bauersachs J. Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction. Hypertension. 2007;50:919-925.
8. Ullian ME, Schelling JR, Linas SL. Aldosterone enhances angiotensin II receptor binding and inositol phosphate responses. Hypertension. 1992; 20:67-73.
9. Coyle CH, Martinez LJ, Coleman MC, Spitz DR, Weintraub NL, Kader KN. Mechanisms of H2O2-induced oxidative stress in endothelial cells. Free Radic Biol Med. 2006;40:2206-2213.
10. Fukui T, Ishizaka N, Rajapopalan S, Laursen JB, Capers Q, Taylor WR, Harrison DG, deLeon H, Wilcox JN, Griendling KK. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res. 1997;80:45-51.
11. Hirono Y, Yoshimoto T, Suzuki N, Sugiyama T, Sakurada M, Takai S, Kobayashi N, Shichiri M, Hirata Y. Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. Endocrinology. 2007;148:1688-1696.
12. Marumo T, Schini-Kerth VB, Brandes RP, Busse R. Glucocorticoids inhibit superoxide anion production and p22phox mRNA expression in human aortic smooth muscle cells. Hypertension. 1998;32:1083-1088.